Skip to main content
Erschienen in: Clinical Rheumatology 9/2022

07.06.2022 | Original Article

Osteoporosis in patients with rheumatoid arthritis is associated with serum immune regulatory cellular factors

verfasst von: Jianjun Qiu, Chunde Lu, Lei Zhang, Xu Zhou, Hanlin Zou

Erschienen in: Clinical Rheumatology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

Osteoporosis (OP) is a comorbidity of rheumatoid arthritis (RA) that largely causes disability. This study discussed the expression patterns of serum immunoregulatory factors and their clinical significance in RA patients complicated with OP.

Methods

A total of 116 RA patients were enrolled. Bone mineral density (BMD) was measured using dual energy X-ray absorptiometry to allocate patients to OP group (N = 62) and non-OP group (N = 54). CRP, rheumatoid factor, IgG, IgA, and IgM were detected using rate nephelometry. Erythrocyte sedimentation rate (ESR) and bone metabolic indexes were detected using Microsed automatic ESR analyzer and Cobas e601 automated immunoassay systems and reagents. IL-17, IL-6, TNF-α, IL-10, and IL-4 levels were determined using ELISA kit and their prediction values on OP were analyzed using the ROC curve. Influencing factors of OP incidence were analyzed using logistic regression model.

Results

RA patients with OP showed increased age, disease course, tender and swollen joints, ESR, CRP, DAS28 scores, β-CTX, IL-17, IL-6, and TNF-α, and decreased 25(OH)D3, IL-10, and IL-4. DAS28 was positively correlated with IL-17, IL-6, and TNF-α, and negatively correlated with IL-10 and IL-4. DAS28, IL-17, IL-10, and IL-4 were independently correlated with OP in RA patients. The combination of DAS28, IL-17, IL-10, and IL-4 can better predict the incidence of OP complication in RA patients.

Conclusion

IL-17, IL-6, TNF-α, IL-10, and IL-4 were associated with disease activity of RA patients complicated with OP. A combination of DAS28, IL-17, IL-10, and IL-4 might predict OP incidence in RA patients.
Key Points
• OP in RA patients shows an association with serum immunoregulatory factors.
• Moreover, the combination of DAS28, IL-17, IL-10, and IL-4 could predict the incidence of OP in RA patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Guo X, Ji J, Zhang J, Hou X, Fu X, Luo Y, Mei Z, Feng Z (2021) Anti-inflammatory and osteoprotective effects of Chikusetsusaponin a on rheumatoid arthritis via the JAK/STAT signaling pathway. Phytomedicine 93:153801PubMedCrossRef Guo X, Ji J, Zhang J, Hou X, Fu X, Luo Y, Mei Z, Feng Z (2021) Anti-inflammatory and osteoprotective effects of Chikusetsusaponin a on rheumatoid arthritis via the JAK/STAT signaling pathway. Phytomedicine 93:153801PubMedCrossRef
3.
Zurück zum Zitat Hashimoto T, Yoshida K, Hashiramoto A, Matsui K (2021) Cell-free DNA in rheumatoid arthritis. Int J Mol Sci 22(16) Hashimoto T, Yoshida K, Hashiramoto A, Matsui K (2021) Cell-free DNA in rheumatoid arthritis. Int J Mol Sci 22(16)
4.
Zurück zum Zitat Scherer HU, Haupl T, Burmester GR (2020) The etiology of rheumatoid arthritis. J Autoimmun 110:102400PubMedCrossRef Scherer HU, Haupl T, Burmester GR (2020) The etiology of rheumatoid arthritis. J Autoimmun 110:102400PubMedCrossRef
5.
Zurück zum Zitat Dai SP, Hsieh WS, Chen CH, Lu YH, Huang HS, Chang DM, Huang SL, Sun WH (2020) TDAG8 deficiency reduces satellite glial number and pro-inflammatory macrophage number to relieve rheumatoid arthritis disease severity and chronic pain. J Neuroinflammation 17(1):170PubMedPubMedCentralCrossRef Dai SP, Hsieh WS, Chen CH, Lu YH, Huang HS, Chang DM, Huang SL, Sun WH (2020) TDAG8 deficiency reduces satellite glial number and pro-inflammatory macrophage number to relieve rheumatoid arthritis disease severity and chronic pain. J Neuroinflammation 17(1):170PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Casanova-Vallve N, Constantin-Teodosiu D, Filer A, Hardy RS, Greenhaff PL, Chapman V (2020) Skeletal muscle dysregulation in rheumatoid arthritis: metabolic and molecular markers in a rodent model and patients. PLoS One 15(7):e0235702PubMedPubMedCentralCrossRef Casanova-Vallve N, Constantin-Teodosiu D, Filer A, Hardy RS, Greenhaff PL, Chapman V (2020) Skeletal muscle dysregulation in rheumatoid arthritis: metabolic and molecular markers in a rodent model and patients. PLoS One 15(7):e0235702PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Stein BE, Hassanzadeh H, Jain A, Lemma MA, Cohen DB, Kebaish KM (2014) Changing trends in cervical spine fusions in patients with rheumatoid arthritis. Spine (Phila Pa 1976) 39(15):1178–1182CrossRef Stein BE, Hassanzadeh H, Jain A, Lemma MA, Cohen DB, Kebaish KM (2014) Changing trends in cervical spine fusions in patients with rheumatoid arthritis. Spine (Phila Pa 1976) 39(15):1178–1182CrossRef
8.
Zurück zum Zitat Buttgereit F, Palmowski A (2021) How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis. Joint Bone Spine 89(1):105285PubMedCrossRef Buttgereit F, Palmowski A (2021) How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis. Joint Bone Spine 89(1):105285PubMedCrossRef
9.
Zurück zum Zitat Emmungil H, Yildiz F, Gozukara MY, Acikalin A (2015) Rheumatoid pleural effusion with nodular pleuritis. A rare presentation of rheumatoid arthritis. Z Rheumatol 74(1):72–74PubMedCrossRef Emmungil H, Yildiz F, Gozukara MY, Acikalin A (2015) Rheumatoid pleural effusion with nodular pleuritis. A rare presentation of rheumatoid arthritis. Z Rheumatol 74(1):72–74PubMedCrossRef
10.
Zurück zum Zitat Gecmen C, Gecmen GG, Kahyaoglu M, Ece D, Ozkan B, Karaman O, Naser A, Kalayci A, Karabay CY, Kirma C (2016) Pericardial effusion due to cholesterol pericarditis in case of rheumatoid arthritis. Echocardiography 33(10):1614–1616PubMedCrossRef Gecmen C, Gecmen GG, Kahyaoglu M, Ece D, Ozkan B, Karaman O, Naser A, Kalayci A, Karabay CY, Kirma C (2016) Pericardial effusion due to cholesterol pericarditis in case of rheumatoid arthritis. Echocardiography 33(10):1614–1616PubMedCrossRef
11.
Zurück zum Zitat Hewlett S, Almeida C, Ambler N, Blair PS, Choy E, Dures E, Hammond A, Hollingworth W, Kadir B, Kirwan J, Plummer Z, Rooke C, Thorn J, Turner N, Pollock J (2019) Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. Health Technol Assess 23(57):1–130PubMedPubMedCentralCrossRef Hewlett S, Almeida C, Ambler N, Blair PS, Choy E, Dures E, Hammond A, Hollingworth W, Kadir B, Kirwan J, Plummer Z, Rooke C, Thorn J, Turner N, Pollock J (2019) Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. Health Technol Assess 23(57):1–130PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Li Y, Jiang L, Zhang Z, Li H, Jiang L, Wang L, Li Z (2019) Clinical characteristics of rheumatoid arthritis patients with peripheral neuropathy and potential related risk factors. Clin Rheumatol 38(8):2099–2107PubMedCrossRef Li Y, Jiang L, Zhang Z, Li H, Jiang L, Wang L, Li Z (2019) Clinical characteristics of rheumatoid arthritis patients with peripheral neuropathy and potential related risk factors. Clin Rheumatol 38(8):2099–2107PubMedCrossRef
13.
Zurück zum Zitat Wu D, Cline-Smith A, Shashkova E, Perla A, Katyal A, Aurora R (2021) T-cell mediated inflammation in postmenopausal osteoporosis. Front Immunol 12:687551PubMedPubMedCentralCrossRef Wu D, Cline-Smith A, Shashkova E, Perla A, Katyal A, Aurora R (2021) T-cell mediated inflammation in postmenopausal osteoporosis. Front Immunol 12:687551PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Perrier-Cornet J, Omorou AY, Fauny M, Loeuille D, Chary-Valckenaere I (2019) Opportunistic screening for osteoporosis using thoraco-abdomino-pelvic CT-scan assessing the vertebral density in rheumatoid arthritis patients. Osteoporos Int 30(6):1215–1222PubMedCrossRef Perrier-Cornet J, Omorou AY, Fauny M, Loeuille D, Chary-Valckenaere I (2019) Opportunistic screening for osteoporosis using thoraco-abdomino-pelvic CT-scan assessing the vertebral density in rheumatoid arthritis patients. Osteoporos Int 30(6):1215–1222PubMedCrossRef
15.
Zurück zum Zitat Xie J, Li S, Xiao L, Ouyang G, Zheng L, Gu Y, Gao C, Han X (2019) Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients. J Orthop Surg Res 14(1):421PubMedPubMedCentralCrossRef Xie J, Li S, Xiao L, Ouyang G, Zheng L, Gu Y, Gao C, Han X (2019) Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients. J Orthop Surg Res 14(1):421PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Gamsjaeger S, Fratzl P, Paschalis EP (2021) Interplay between mineral crystallinity and mineral accumulation in health and postmenopausal osteoporosis. Acta Biomater 124:374–381PubMedCrossRef Gamsjaeger S, Fratzl P, Paschalis EP (2021) Interplay between mineral crystallinity and mineral accumulation in health and postmenopausal osteoporosis. Acta Biomater 124:374–381PubMedCrossRef
17.
Zurück zum Zitat Lee HN, Kim A, Kim Y, Kim GT, Sohn DH, Lee SG (2020) Higher serum uric acid levels are associated with reduced risk of hip osteoporosis in postmenopausal women with rheumatoid arthritis. Medicine (Baltimore) 99(24):e20633CrossRef Lee HN, Kim A, Kim Y, Kim GT, Sohn DH, Lee SG (2020) Higher serum uric acid levels are associated with reduced risk of hip osteoporosis in postmenopausal women with rheumatoid arthritis. Medicine (Baltimore) 99(24):e20633CrossRef
18.
Zurück zum Zitat Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Peeters AJ, de Jonge-Bok JM, Breedveld FC, Dijkmans BA, Allaart CF, Lems WF (2007) Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis 66(11):1508–1512PubMedPubMedCentralCrossRef Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Peeters AJ, de Jonge-Bok JM, Breedveld FC, Dijkmans BA, Allaart CF, Lems WF (2007) Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis 66(11):1508–1512PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, Frediani B, Cantatore F, Pellerito R, Bartolone S, La Montagna G, Adami S (2000) A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 27(11):2582–2589PubMed Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, Frediani B, Cantatore F, Pellerito R, Bartolone S, La Montagna G, Adami S (2000) A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 27(11):2582–2589PubMed
20.
Zurück zum Zitat Abdel Meguid MH, Hamad YH, Swilam RS, Barakat MS (2013) Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol Int 33(3):697–703PubMedCrossRef Abdel Meguid MH, Hamad YH, Swilam RS, Barakat MS (2013) Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol Int 33(3):697–703PubMedCrossRef
21.
Zurück zum Zitat Suh CH, Yoo DH, Berrocal Kasay A, Chalouhi El-Khouri E, Cons Molina FF, Shesternya P, Miranda P, Medina-Rodriguez FG, Wiland P, Jeka S, Chavez-Corrales J, Linde T, Hrycaj P, Abello-Banfi M, Hospodarskyy I, Jaworski J, Piotrowski M, Brzosko M, Krogulec M et al (2019) Long-term efficacy and safety of biosimilar CT-P10 versus innovator rituximab in rheumatoid arthritis: 48-week results from a randomized phase III trial. BioDrugs 33(1):79–91PubMedPubMedCentralCrossRef Suh CH, Yoo DH, Berrocal Kasay A, Chalouhi El-Khouri E, Cons Molina FF, Shesternya P, Miranda P, Medina-Rodriguez FG, Wiland P, Jeka S, Chavez-Corrales J, Linde T, Hrycaj P, Abello-Banfi M, Hospodarskyy I, Jaworski J, Piotrowski M, Brzosko M, Krogulec M et al (2019) Long-term efficacy and safety of biosimilar CT-P10 versus innovator rituximab in rheumatoid arthritis: 48-week results from a randomized phase III trial. BioDrugs 33(1):79–91PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Shim SC, Bozic-Majstorovic L, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Cons Molina FF, Medina-Rodriguez FG, Miranda P, Shesternya P, Chavez-Corrales J, Wiland P, Jeka S, Garmish O, Hrycaj P, Fomina N, Park W, Suh CH, Lee SJ, Lee SY et al (2019) Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. Rheumatology (Oxford) 58(12):2193–2202CrossRef Shim SC, Bozic-Majstorovic L, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Cons Molina FF, Medina-Rodriguez FG, Miranda P, Shesternya P, Chavez-Corrales J, Wiland P, Jeka S, Garmish O, Hrycaj P, Fomina N, Park W, Suh CH, Lee SJ, Lee SY et al (2019) Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. Rheumatology (Oxford) 58(12):2193–2202CrossRef
23.
Zurück zum Zitat Yoo DH, Suh CH, Shim SC, Jeka S, Molina FFC, Hrycaj P, Wiland P, Lee EY, Medina-Rodriguez FG, Shesternya P, Radominski S, Stanislav M, Kovalenko V, Sheen DH, Myasoutova L, Lim MJ, Choe JY, Lee SJ, Lee SY et al (2017) Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar CT-P10 versus innovator rituximab in patients with rheumatoid arthritis: results up to week 72 of a phase I randomized controlled trial. BioDrugs 31(4):357–367PubMedPubMedCentralCrossRef Yoo DH, Suh CH, Shim SC, Jeka S, Molina FFC, Hrycaj P, Wiland P, Lee EY, Medina-Rodriguez FG, Shesternya P, Radominski S, Stanislav M, Kovalenko V, Sheen DH, Myasoutova L, Lim MJ, Choe JY, Lee SJ, Lee SY et al (2017) Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar CT-P10 versus innovator rituximab in patients with rheumatoid arthritis: results up to week 72 of a phase I randomized controlled trial. BioDrugs 31(4):357–367PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Danks L, Sabokbar A, Gundle R, Athanasou NA (2002) Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann Rheum Dis 61(10):916–921PubMedPubMedCentralCrossRef Danks L, Sabokbar A, Gundle R, Athanasou NA (2002) Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann Rheum Dis 61(10):916–921PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Dijsselbloem N, Vanden Berghe W, De Naeyer A, Haegeman G (2004) Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. Biochem Pharmacol 68(6):1171–1185PubMedCrossRef Dijsselbloem N, Vanden Berghe W, De Naeyer A, Haegeman G (2004) Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. Biochem Pharmacol 68(6):1171–1185PubMedCrossRef
26.
Zurück zum Zitat Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581PubMedCrossRef Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581PubMedCrossRef
27.
Zurück zum Zitat Richards AM, Coleman NW, Knight TA, Belkoff SM, Mears SC (2010) Bone density and cortical thickness in normal, osteopenic, and osteoporotic sacra. J Osteoporos 2010 Richards AM, Coleman NW, Knight TA, Belkoff SM, Mears SC (2010) Bone density and cortical thickness in normal, osteopenic, and osteoporotic sacra. J Osteoporos 2010
28.
Zurück zum Zitat Naruo M, Negishi Y, Okuda T, Katsuyama M, Okazaki K, Morita R (2021) Alcohol consumption induces murine osteoporosis by downregulation of natural killer T-like cell activity. Immun Inflamm Dis 9(4):1370–1382PubMedPubMedCentralCrossRef Naruo M, Negishi Y, Okuda T, Katsuyama M, Okazaki K, Morita R (2021) Alcohol consumption induces murine osteoporosis by downregulation of natural killer T-like cell activity. Immun Inflamm Dis 9(4):1370–1382PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Littlejohn EA, Monrad SU (2018) Early diagnosis and treatment of rheumatoid arthritis. Prim Care 45(2):237–255PubMedCrossRef Littlejohn EA, Monrad SU (2018) Early diagnosis and treatment of rheumatoid arthritis. Prim Care 45(2):237–255PubMedCrossRef
30.
Zurück zum Zitat Llorente I, Garcia-Castaneda N, Valero C, Gonzalez-Alvaro I, Castaneda S (2020) Osteoporosis in rheumatoid arthritis: dangerous liaisons. Front Med (Lausanne) 7:601618CrossRef Llorente I, Garcia-Castaneda N, Valero C, Gonzalez-Alvaro I, Castaneda S (2020) Osteoporosis in rheumatoid arthritis: dangerous liaisons. Front Med (Lausanne) 7:601618CrossRef
31.
Zurück zum Zitat Foger-Samwald U, Dovjak P, Azizi-Semrad U, Kerschan-Schindl K, Pietschmann P (2020) Osteoporosis: pathophysiology and therapeutic options. EXCLI J 19:1017–1037PubMedPubMedCentral Foger-Samwald U, Dovjak P, Azizi-Semrad U, Kerschan-Schindl K, Pietschmann P (2020) Osteoporosis: pathophysiology and therapeutic options. EXCLI J 19:1017–1037PubMedPubMedCentral
32.
Zurück zum Zitat Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360–1372PubMedCrossRef Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360–1372PubMedCrossRef
33.
Zurück zum Zitat Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL (2019) Sex and management of rheumatoid arthritis. Clin Rev Allergy Immunol 56(3):333–345PubMedCrossRef Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL (2019) Sex and management of rheumatoid arthritis. Clin Rev Allergy Immunol 56(3):333–345PubMedCrossRef
34.
Zurück zum Zitat Wang J, Yan D, Zhao A, Hou X, Zheng X, Chen P, Bao Y, Jia W, Hu C, Zhang ZL, Jia W (2019) Discovery of potential biomarkers for osteoporosis using LC-MS/MS metabolomic methods. Osteoporos Int 30(7):1491–1499PubMedCrossRef Wang J, Yan D, Zhao A, Hou X, Zheng X, Chen P, Bao Y, Jia W, Hu C, Zhang ZL, Jia W (2019) Discovery of potential biomarkers for osteoporosis using LC-MS/MS metabolomic methods. Osteoporos Int 30(7):1491–1499PubMedCrossRef
35.
Zurück zum Zitat Hoes JN, Bultink IE, Lems WF (2015) Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother 16(4):559–571PubMedCrossRef Hoes JN, Bultink IE, Lems WF (2015) Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother 16(4):559–571PubMedCrossRef
37.
Zurück zum Zitat Tyagi AM, Srivastava K, Mansoori MN, Trivedi R, Chattopadhyay N, Singh D (2012) Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One 7(9):e44552PubMedPubMedCentralCrossRef Tyagi AM, Srivastava K, Mansoori MN, Trivedi R, Chattopadhyay N, Singh D (2012) Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One 7(9):e44552PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Wang T, He C (2020) TNF-alpha and IL-6: the link between immune and bone system. Curr Drug Targets 21(3):213–227PubMed Wang T, He C (2020) TNF-alpha and IL-6: the link between immune and bone system. Curr Drug Targets 21(3):213–227PubMed
39.
Zurück zum Zitat Azizieh F, Raghupathy R, Shehab D, Al-Jarallah K, Gupta R (2017) Cytokine profiles in osteoporosis suggest a proresorptive bias. Menopause 24(9):1057–1064PubMedCrossRef Azizieh F, Raghupathy R, Shehab D, Al-Jarallah K, Gupta R (2017) Cytokine profiles in osteoporosis suggest a proresorptive bias. Menopause 24(9):1057–1064PubMedCrossRef
40.
Zurück zum Zitat Yan X, Xu Z, Li S, Yan L, Lyu G, Wang Z (2021) Establishment and verification of an osteoporosis risk model in patients with rheumatoid arthritis: a valuable new model. Arch Osteoporos 16(1):3PubMedPubMedCentralCrossRef Yan X, Xu Z, Li S, Yan L, Lyu G, Wang Z (2021) Establishment and verification of an osteoporosis risk model in patients with rheumatoid arthritis: a valuable new model. Arch Osteoporos 16(1):3PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX, Jiang YF (2014) Plasma levels of IL-37 and correlation with TNF-alpha, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS One 9(5):e95346PubMedPubMedCentralCrossRef Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX, Jiang YF (2014) Plasma levels of IL-37 and correlation with TNF-alpha, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS One 9(5):e95346PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat DeSelm CJ, Takahata Y, Warren J, Chappel JC, Khan T, Li X, Liu C, Choi Y, Kim YF, Zou W, Teitelbaum SL (2012) IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem 113(9):2895–2902PubMedPubMedCentralCrossRef DeSelm CJ, Takahata Y, Warren J, Chappel JC, Khan T, Li X, Liu C, Choi Y, Kim YF, Zou W, Teitelbaum SL (2012) IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem 113(9):2895–2902PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Tu MY, Han KY, Lan YW, Chang KY, Lai CW, Staniczek T, Lai CY, Chong KY, Chen CM (2021) Association of TGF-beta1 and IL-10 gene polymorphisms with osteoporosis in a study of Taiwanese osteoporotic patients. Genes (Basel) 12(6) Tu MY, Han KY, Lan YW, Chang KY, Lai CW, Staniczek T, Lai CY, Chong KY, Chen CM (2021) Association of TGF-beta1 and IL-10 gene polymorphisms with osteoporosis in a study of Taiwanese osteoporotic patients. Genes (Basel) 12(6)
44.
Zurück zum Zitat De Martinis M, Ginaldi L, Sirufo MM, Bassino EM, De Pietro F, Pioggia G, Gangemi S (2020) IL-33/vitamin D crosstalk in psoriasis-associated osteoporosis. Front Immunol 11:604055PubMedCrossRef De Martinis M, Ginaldi L, Sirufo MM, Bassino EM, De Pietro F, Pioggia G, Gangemi S (2020) IL-33/vitamin D crosstalk in psoriasis-associated osteoporosis. Front Immunol 11:604055PubMedCrossRef
45.
Zurück zum Zitat van Riel PL, Renskers L (2016) The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol 34(5 Suppl 101):S40–S44PubMed van Riel PL, Renskers L (2016) The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol 34(5 Suppl 101):S40–S44PubMed
46.
Zurück zum Zitat Lu L, Liu Y, Nazierhan S, Sun Z, Aikeremu D, Alimasi W, Xu K, Niyazi W, Wang H (2020) Expression changes of IL-17 in zoledronic acid combined with PVP technology in the treatment of postmenopausal osteoporotic vertebral compression fracture and its predictive value of relapse. J Musculoskelet Neuronal Interact 20(4):563–569PubMedPubMedCentral Lu L, Liu Y, Nazierhan S, Sun Z, Aikeremu D, Alimasi W, Xu K, Niyazi W, Wang H (2020) Expression changes of IL-17 in zoledronic acid combined with PVP technology in the treatment of postmenopausal osteoporotic vertebral compression fracture and its predictive value of relapse. J Musculoskelet Neuronal Interact 20(4):563–569PubMedPubMedCentral
47.
Zurück zum Zitat Qu CH, Hou Y, Bi YF, Han QR, Jiao CH, Zou QF (2019) Diagnostic values of serum IL-10 and IL-17 in rheumatoid arthritis and their correlation with serum 14-3-3eta protein. Eur Rev Med Pharmacol Sci 23(5):1899–1906PubMed Qu CH, Hou Y, Bi YF, Han QR, Jiao CH, Zou QF (2019) Diagnostic values of serum IL-10 and IL-17 in rheumatoid arthritis and their correlation with serum 14-3-3eta protein. Eur Rev Med Pharmacol Sci 23(5):1899–1906PubMed
48.
Zurück zum Zitat Froschen FS, Schell S, Schildberg FA, Klausing A, Kohlhof H, Gravius S, Randau TM (2020) Analysis of synovial biomarkers with a multiplex protein microarray in patients with PJI undergoing revision arthroplasty of the hip or knee joint. Arch Orthop Trauma Surg 140(12):1883–1890PubMedCrossRef Froschen FS, Schell S, Schildberg FA, Klausing A, Kohlhof H, Gravius S, Randau TM (2020) Analysis of synovial biomarkers with a multiplex protein microarray in patients with PJI undergoing revision arthroplasty of the hip or knee joint. Arch Orthop Trauma Surg 140(12):1883–1890PubMedCrossRef
Metadaten
Titel
Osteoporosis in patients with rheumatoid arthritis is associated with serum immune regulatory cellular factors
verfasst von
Jianjun Qiu
Chunde Lu
Lei Zhang
Xu Zhou
Hanlin Zou
Publikationsdatum
07.06.2022
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 9/2022
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-022-06212-0

Weitere Artikel der Ausgabe 9/2022

Clinical Rheumatology 9/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.